Abstract
Purpose
This review primarily aims to review the epidemiology, clinical characteristics, imaging, pathology, immunohistochemistry, diagnosis, differential diagnosis, treatment, and prognosis of Primary pulmonary myxoid sarcoma (PPMS) with EWS RNA binding protein 1::cAMP response element binding protein 1 (EWSR1::CREB1) fusion. It provides reference for the diagnosis and treatment of this disease.
Methods
Retrospectively collected the literature about PPMS with EWSR1::CREB1 fusion, its clinical, radiology, histology, molecular characteristics and current treatment strategies were collated and analyzed. This review provides a detailed differential diagnosis of the disease.
Results
PPMS is an exceptionally rare, low-grade malignant tumor of the lung. This tumor commonly infiltrates lung tissue and develops within bronchial passages. It is identified by a genetic rearrangement involving the EWSR1 gene and a distinct chromosomal translocation t(2; 22)(q33; q12). Variants include EWSR1::CREB1 fusion and EWS RNA binding protein 1::activating transcription factors (EWSR1::ATF1) fusion. PPMS with EWSR1::CREB1 fusion is more prevalent among middle-aged individuals and affects both sexes almost equally. Clinical symptoms are relatively non-specific, primarily including cough, hemoptysis, and weight loss. Most patients undergo surgery and experience a favorable prognosis. Further research is required to validate the effectiveness of alternative treatments for PPMS with EWSR1::CREB1 fusion.
Conclusion
EWSR1 rearrangement and EWSR1::CREB1 fusion are crucial genetic features of PPMS and serve as important diagnostic markers. Immunohistochemically, PPMS tests positive for EMA. In terms of treatment, surgery has been the primary approach in recent years. Therefore, the efficacy of other treatments still requires further investigation.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Primary pulmonary myxoid sarcoma (PPMS) is an exceedingly rare, low-grade malignant sarcoma. It was initially described as a primary pulmonary endobronchial myxoid tumor in the study of Nicholson AG et al. in 1999 (Nicholson et al. 1999). PPMS stands out due to its distinctive morphological and genetic traits, notably the presence of the EWS RNA binding protein 1::cAMP response element binding protein 1 (EWSR1::CREB1) fusion gene and a remarkably low Ki-67 proliferation index (Wu et al. 2021). Thway K and associates further uncovered the relationship between characteristic chromosomal translocation t(2; 22) (q33; q12) and the occurrence of EWSR1::CREB1 fusion (Thway et al. 2011). PPMS was first recognized by World Health Organization (WHO) classification in 2015, which belonged to the category of mesenchymal tumors. Then it was classified as mesenchymal tumors specific to the lung in the 2021 WHO Classification of Lung Tumors (Travis et al. 2015; Nicholson et al. 2022). PPMS originates from mesenchymal components in the bronchial wall, pulmonary stroma, or blood vessels (Gołota et al. 2019). Its clinical presentation is generally unspecific, sometimes detectable only through physical examination, making it challenging to differentiate from other lung tumors. This article primarily aims to review the epidemiology, clinical characteristics, imaging, pathology, immunohistochemistry, diagnosis, differential diagnosis, treatment, and prognosis of PPMS with EWSR1::CREB1 fusion.
Epidemiology and clinical characteristics
PPMS is an exceptionally rare, low-grade sarcoma, with a total of 39 clinical cases compiled in Table 1 (Nicholson et al. 1999; Wu et al. 2021; Thway et al. 2011; Matsukuma et al. 2012; Chen et al. 2020; Inayama et al. 2001; Smith et al. 2014; Jeon et al. 2014; Kim et al. 2017; Yanagida et al. 2017; Agaimy et al. 2017; Koelsche et al. 2020; Opitz et al. 2019; Nishimura et al. 2023; Prieto-Granada et al. 2017). Most of the symptoms of PPMS that manifest clinically are non-specific, such as cough, hemoptysis, and weight loss. Among the 39 cases, 20 were in female patients and 19 in male patients, resulting in a male-to-female ratio of 0.95:1. The age range of PPMS cases spanned from 21 to 80 years, with a median age of 43.6. Among the documented cases, 12 individuals had never smoked, while 11 had a history of smoking. This suggests that the occurrence of PPMS is not directly linked to smoking history. PPMS does not display a specific predilection for a particular location within the lung; it can invade both the right and left lungs, though it is more frequently found in the right lung (59%, 23/39). PPMS commonly infiltrates bronchial tissues, with a tendency toward endobronchial growth observed in 17 out of 39 cases, while 4 cases exhibited no endobronchial involvement, and the remaining cases did not provide sufficient information. Nonetheless, this tumor can also develop outside the lung parenchyma, occurring within an interlobar fissure without parenchymal invasion (Kim et al. 2017).
Imaging characteristics
Currently, CT scans serve as the primary imaging modality for PPMS diagnosis, with X-rays providing supplementary assistance. However, the specific imaging features of this tumor remain somewhat uncertain. Existing literature reviews and pathology reports on PPMS emphasize the significance of CT findings in enhancing our understanding of the disease. On CT scans, PPMS is frequently found in close proximity to the bronchi and often infiltrates the lung parenchyma. Most PPMS cases observed in imaging reports indicate that the primary lung masses are predominantly located in the right lower lobe (28%, 11/39) and right upper lobe (23%, 9/39). These tumors typically appear as well-defined solid masses with sizes ranging from 1.4 cm to 14 cm. Contrast-enhanced CT scans typically reveal these lesions as mildly and heterogeneously enhanced masses (Yuliana and Hayati 2022), with contrast enhancement in both solid and cystic components. Additionally, X-ray images of PPMS exhibit a lung field mass shadow, which may resemble a pleural effusion (Yuliana and Hayati 2022).
Histopathologic characteristics
Macroscopically, PPMS lesions typically manifest as solitary, well-defined masses with a lobulated appearance and a pale, crystalline cut surface. These tumors vary in size, ranging from 1.4 cm to 14 cm, with an average size of 5 cm. Microscopically, most cases exhibit a lobulated architecture, featuring a reticular network composed of delicate, lace-like strands and cords of ovoid, spindle, or stellate cells within a prominent myxoid matrix. Thway et al. (2011) reported clinicopathological data on 10 PPMS cases, which displayed cords of polygonal, spindle, or stellate cells embedded within a myxoid stroma, resembling extraskeletal myxoid chondrosarcoma. Two cases described by Nicholson et al. (1999) demonstrated interweaving cords of small, uniform, rounded, or slightly elongated cells within a myxoid stroma. The stroma displayed positive staining with Alcian blue and was sensitive to hyaluronidase. Tumor cells contained a small amount of periodic acid-Schiff-positive eosinophilic cytoplasm. Ultrastructural studies revealed an excess of rough endoplasmic reticulum in tumor cells, with some cisternae appearing dilated and scalloping of cell surfaces, although no intracisternal tubules were identified (Nicholson et al. 1999). In most cases, a patchy background of inflammatory cells, primarily consisting of lymphocytes and plasma cells, is present, contributing to the tumor’s infiltrative appearance and occasional focal necrosis and inflammation. Additionally, Chen et al. (2020) expanded the morphological and cytological spectrum of PPMS. They documented an additional case of this rare tumor and reported the first occurrence of chondrocyte-like and physaliferous-like tumor cells within this tumor, with a more intense inflammatory infiltrate in their case. Furthermore, PPMS often exhibits mild to moderate atypia; in the study by Thway et al. (2011), four cases displayed no or minimal atypia, six showed focal pleomorphism, and five had necrosis. Mitotic indices varied, with most tumors not exceeding 5 mitoses per 10 high-power fields (Fig. 1).
Molecular genetics and immunohistochemistry
Recent studies have confirmed that the critical genetic feature of PPMS is the rearrangement of the EWSR1 gene and the formation of the EWSR1::CREB1 fusion gene. This genetic alteration serves as a crucial diagnostic marker. To identify the EWSR1 gene rearrangement, fluorescence in situ hybridization (FISH) can be conducted on formalin-fixed paraffin-embedded (FFPE) tissue samples. This test significantly enhances diagnostic accuracy. In Table 2 (Nicholson et al. 1999; Wu et al. 2021; Thway et al. 2011; Matsukuma et al. 2012; Chen et al. 2020; Inayama et al. 2001; Smith et al. 2014; Jeon et al. 2014; Kim et al. 2017; Yanagida et al. 2017; Agaimy et al. 2017; Koelsche et al. 2020; Opitz et al. 2019; Nishimura et al. 2023; Prieto-Granada et al. 2017), which compiles the 39 PPMS cases, FISH analysis was performed in 34 cases, revealing a positive EWSR1 gene rearrangement rate of 85% (29/34). Furthermore, the presence of the EWSR1::CREB1 fusion can be demonstrated through reverse transcription-polymerase chain reaction (RT-PCR) targeting specific fusion transcripts. EWSR1::CREB1 fusion is commonly found in various mesenchymal tumors occurring at different sites, displaying a broad spectrum of biological behaviors (Bale et al. 2018). Of the 26 cases in which RT-PCR was performed, the positive rate of EWSR1::CREB1 fusion is 73% (19/26). EWSR1::CREB1 fusion is an important characteristic of PPMS; however, it is essential to note that this fusion is not exclusive to PPMS but is also observed in other neoplasms, including angiomatoid fibrous histiocytoma (AFH), clear cell sarcoma, hyalinising clear cell carcinoma of the salivary gland, and clear cell carcinoma of the soft tissue or gastrointestinal tract (Thway and Fisher 2012; Cazzato et al. 2022; Stockman et al. 2012; Rossi et al. 2007). Additionally, Nishimura T et al. (Nishimura et al. 2023) reported a unique case of PPMS, harboring an EWSR1::ATF1 gene fusion. Both ATF1 and CREB1, belonging to the CREB family, can create fusion genes with EWSR1 (Kao et al. 2017). If an EWSR1::ATF1 fusion is detected in pulmonary myxoid sarcoma with EWSR1::CREB1 translocation, the tumor may be classified as “pulmonary myxoid sarcoma with EWSR1::CREB translocation” (Hashimoto et al. 2019).
PPMS lacks highly specific immunohistochemical markers. Immunohistochemical analysis has shown that tumor cells consistently express epithelial membrane antigen (EMA) (Wu et al. 2021). Conversely, they do not exhibit immunoreactivity for cytokeratin (CK), thyroid transcription factor-1 (TTF-1), napsin A, S-100 protein, CAM5.2, CD10, CD31, CD34, desmin, smooth-muscle actin (SMA), p63, calponin, h-caldesmon, anaplastic lymphoma kinase (ALK), c-kit, melanocytic markers (HMB-45), synaptophysin, or glial fibrillary acid protein (GFAP) (Chen et al. 2020).
The key genetic characteristics of PPMS involve EWSR1 rearrangement and EWSR1::CREB1 fusion. Additionally, immunohistochemistry typically reveals positivity for EMA. The combination of these genetic and immunohistochemical features aids in the diagnosis of this tumor.
Diagnosis and differential diagnosis
PPMS lacks distinctive clinical manifestations, and routine blood tests and tumor marker levels typically fall within the normal range, making it challenging to differentiate from other lung conditions with similar clinical presentations. Therefore, the diagnosis of PPMS primarily relies on the tumor's location and histopathological features. Pathological diagnosis is typically obtained through needle biopsy, which serves as the gold standard for clinical diagnosis and holds significant importance for patient management. Differential diagnosis is crucial in the evaluation of PPMS. PPMS should be distinguished from several thoracic tumors:
Extraskeletal myxoid chondrosarcoma (EMC)
EMC is a rare tumor characterized by multinodular growth and short anastomotic strands of oval to spindle-shaped cells embedded in a rich myxoid matrix (Balanzá et al. 2016; Zhou et al. 2012). EMC possesses distinct ultrastructural features, with cords of cells immersed in a matrix rich in glycosaminoglycans (Goh et al. 2001). The key distinguishing factor between PPMS and EMC is their genetic differences. Genetically, gene fusions involving nuclear receptor subfamily 4 group A member 3 (NR4A3) and resulting in NR4A3 constitutive expression are exclusive to EMC and considered a hallmark of the disease (Stacchiotti et al. 2020). The primary fusion genes identified in EMC are EWSR1::NR4A3 and TATA-box binding protein-associated factor 15::nuclear receptor subfamily 4 group A member 3 (TAF15::NR4A3) gene fusions (Hisaoka and Hashimoto 2005), whereas PPMS is characterized by the EWSR1::CREB1 gene fusion.
AFH
AFH is a rare soft tissue mesenchymal neoplasm (Thway and Fisher 2015). According to a study by Gui et al. (2020), PPMS overlaps with a myxoid variant of AFH of the soft tissue morphologically. The myxoid variant of AFH occurs mainly in soft tissues and is rarely seen in the lungs, myxoid variant AFH exhibits distinct myxoid features and can often positively express EMA and EWSR1 gene rearrangements. As a result, it is difficult to distinguish from PPMS (Gong et al. 2018). But, the myxoid stroma of pulmonary AFH is usually focal. The most common morphological features of AFH cases include a peritumoral lymphoid cuff and whorled or storiform patterns, which are not typically described in PPMS. Immunophenotype differences also serve as distinguishing factors; AFH often exhibits positivity for CD68, CD163, desmin, EMA, and ALK (Wang et al. 2021). In contrast, PPMS is characterized by positivity for EMA, along with negativity for desmin and ALK. Moreover, low-to-intermediate malignant potential AFH can also exhibit EWSR1::CREB1 fusion due to t(2; 22) (q33; q12) (Antonescu et al. 2007; Costa and Weiss 1990). While EWSR1::ATF1 and fused in sarcoma::activating transcription factor 1 (FUS::ATF1) fusion genes can be detected in AFH, they are rarely found in PPMS cases (Chen et al. 2020).
Gui et al. (2020) noted that PPMS and AFH have similar histological features, clinical manifestations, immunophenotypic and molecular alterations, and that they are closely related in lineage and pathogenesis. However, whether EWSR1-positive PPMS and AFH may represent the lineage of the same disease, and whether they originate from primitive mesenchymal cells driven by the same or similar EWSR1 fusion gene products, remains to be further investigated.
Myoepithelial tumors (MT)
Myoepithelial tumors (MT) exhibit diverse morphological characteristics and immunophenotypes. They typically display a multinodular or lobular growth pattern, consisting of spindled, ovoid, or epithelioid cells. Immunohistochemically, over 44% of MT cases show the presence of EWSR1 gene rearrangement, and most MT cases test positive for CK, p63, S-100 protein, calponin, and SMA (Jo and Fletcher 2015), whereas these markers are negative in PPMS. Additionally, common fusion variants in MT include EWSR1::POU5F1, EWSR1::PBX1, and EWSR1::ZNF444 (Wang et al. 2021), while the primary fusion gene in PPMS is EWSR1::CREB1 fusion gene.
Inflammatory myofibroblastic tumor (IMT)
IMT is a distinct tumor characterized by myofibroblastic spindle cells and accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils (Khatri et al. 2018). IMTs are immunohistochemically positive for SMA, ALK-1, desmin, and calponin (Henriques de Gouveia 2023). Approximately 50–70% of IMTs harbor the ALK gene rearrangement (Gilani and Kowalski 2014), while PPMS is negative for these markers.
Low-grade myxoid liposarcoma (LGML)
LGML is a malignant adipogenic neoplasm with prominent arborizing capillaries, occasional lipoblasts, and primitive spindle cells in a myxoid background. LGML often involves DNA damage-inducible transcript 3 (DDIT3) gene rearrangement (Scapa et al. 2021), which is not present in PPMS.
Pulmonary microcystic fibromyxoma (PMF)
PMF is well circumscribed with notable cystic changes and a myxoid stroma. Microscopically, PMF features innocuous, widely spaced, spindled to stellate tumor cells with minimal nuclear pleomorphism, and no mitotic activity. These uniform nuclei are widely dispersed within a fibromyxoid stroma, which stains positively with Alcian blue and is sensitive to hyaluronidase. PMF is distinct in its unique microcystic histology, which is absent in PPMS. PMF does not exhibit diagnostic molecular genetic changes, and it does not present with endobronchial localization (Shilo et al. 2006) (Fig. 2).
Therapy strategies
Currently, the primary treatment for PPMS with EWSR1::CREB1 fusion is surgery. Given the rarity and non-specific clinical features of PPMS, there are no definite factors known to impact its prognosis.
Surgery
Surgical excision is commonly performed as the primary treatment for all patients with PPMS (Wu et al. 2021). It is essential to closely monitor patients post-surgery to assess the effectiveness of the treatment and the prognosis. PPMS, being a well-defined, low-grade malignant solid sarcoma with a low Ki-67 index, has shown favorable clinical outcomes following surgical resection (Wu et al. 2021). According to existing literature, surgery is the primary treatment approach for most patients. The available surgical excision options include wedge resection, segment resection, lobectomy, and pneumonectomy, depending on tumor size and stage. For instance, Wu et al. (2021) reported a case where a patient with PPMS had primary thyroid cancer with lymph node and lung metastases. In this case, the patient underwent thoracoscopic right upper lobectomy and lymph node dissection, followed by bilateral total thyroidectomy and neck lymph node dissection three months later. There were no signs of recurrence or metastasis during the 12-month follow-up period. Additionally, Kim et al. (2017) described a case where the mass was located in the interlobar fissure of the left lung without definite parenchymal invasion. They successfully removed the mass via video-assisted thoracoscopic surgery without the need for pulmonary parenchymal resection. Thus, a comprehensive treatment approach, with surgery as the primary mode and active management of the primary disease, can improve the condition and quality of life for PPMS patients. Accurate TNM staging and molecular pathological classification can guide postoperative comprehensive treatment. In summary, surgical treatment is the mainstay for PPMS patients and can yield positive outcomes. For patients who are not suitable for surgical resection, alternative treatments such as medication may be considered.
Chemotherapy
Currently, there are limited data on chemotherapy for PPMS, and its effectiveness remains unclear, warranting further investigation. Garnier et al. (2021) initially reported a doxorubicin-based chemotherapy regimen used to treat intracranial non-myxoid angiomatoid fibrous histiocytoma with EWSR1::CREB1 transcript fusion, which resulted in prolonged stable disease for fourteen months after treatment discontinuation. Although PPMS shares the EWSR1::CREB1 fusion with AFH, there have been no reports indicating that doxorubicin can produce a significant therapeutic effect in PPMS with EWSR1::CREB1 fusion. Consequently, the chemotherapy regimens for PPMS with EWSR1::CREB1 fusion remain uncertain.
Molecularly targeted therapy
While EWSR1 gene rearrangement and EWSR1::CREB1 fusion are distinctive features of PPMS, the current understanding of this target remains limited. Therefore, it is necessary to investigate the potential effectiveness of targeted therapy in treating PPMS. Subbiah et al. (2016) have explored the use of the cellular mesenchymal–epithelial transition factor (c-Met)/ALK inhibitor crizotinib and the multi-kinase vascular endothelial growth factor (VEGF) inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor (GNET) with EWSR1::CREB1 fusion. These two drugs demonstrated a sustained, nearly complete response in GNET. Additionally, the study included 11 cases of patients with the same EWSR1::CREB1 fusion, encompassing sarcomas not otherwise specified (NOS), malignant neoplasms of unknown primary, melanoma, and head and neck mucoepidermoid carcinoma. EWSR1::CREB1 fusion was identified as the primary driver in these cases. Subbiah et al. (2016) suggested that patients with this EWSR1::CREB1 fusion could also benefit from crizotinib and pazopanib. Furthermore, Ngo et al. (2022) reported a durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1::CREB1 fusion and ALK overexpression. However, the use of crizotinib and pazopanib in clinical treatment for PPMS with EWSR1::CREB1 fusion has not been studied yet. The effectiveness of these two drugs in PPMS cases with EWSR1::CREB1 fusion remains uncertain, and further data are needed to determine their suitability for treating PPMS with EWSR1::CREB1 fusion.
Prognosis
Based on available research findings, the clinical stage of the tumor, the overall health of the patients, their age, and gender all play significant roles as prognostic factors. Retrospective studies indicate that most patients showed good recovery following surgery, with no evidence of recurrence or metastasis. According to Table 2, the rate of metastasis after surgical interventions for PPMS is 14.7% (5/34), with only one fatality resulting from brain metastases after surgery (Thway et al. 2011). Among the 34 patients who underwent surgery, 85.3% (29/34) survived at the final follow-up with NED. The NED duration for these 29 patients ranged from 0.1 to 15 years, with an average NED of 3.5 years. However, based on retrospective studies, there is no conclusive clinical evidence establishing a direct link between post-surgery metastasis and the presence of EWSR1 gene rearrangement or EWSR1::CREB1 fusion. The role of these genetic abnormalities in predicting the prognosis of PPMS remains uncertain and requires further investigation in the future.
Conclusion
PPMS with EWSR1::CREB1 fusion is an exceedingly rare low-grade malignant sarcoma, typically found in the bronchi and lung parenchyma. Microscopically, PPMS is characterized by a reticular network with delicate lace-like strands and cords of ovoid, spindle, or stellate cells in a prominent myxoid matrix. EWSR1 rearrangement and EWSR1::CREB1 fusion are crucial genetic features of PPMS and serve as important diagnostic markers. Immunohistochemically, PPMS tests positive for EMA. In terms of treatment, surgery has been the primary approach in recent years. Therefore, the efficacy of other treatments such as radiotherapy, chemotherapy, and immunotargeted therapy still requires further investigation.
Data availability
A comprehensive search was performed through PubMed using the literature retrieval strategy “[Primary Pulmonary myxoid sarcoma (Title/Abstract)] AND [EWSR1::CREB1 fusion (Title/Abstract)]” in July 2023. Relevant articles were obtained, and references from each of these articles were further searched for relevant articles. A total of 46 articles were reviewed (15 were case reports or case series).
References
Agaimy A, Duell T, Morresi-Hauf AT (2017) EWSR1-fusion-negative, SMARCB1-deficient primary pulmonary myxoid sarcoma. Polish J Pathol 68(3):261–267. https://doi.org/10.5114/pjp.2017.71535
Antonescu CR, Dal Cin P, Nafa K et al (2007) EWSR1::CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosom Cancer 46(12):1051–1060. https://doi.org/10.1002/gcc.20491
Balanzá R, Arrangoiz R, Cordera F et al (2016) Pulmonary extraskeletal myxoid chondrosarcoma: a case report and literature review. Int J Surg Case Rep 27:96–101. https://doi.org/10.1016/j.ijscr.2016.08.025
Bale TA, Oviedo A, Kozakewich H et al (2018) Intracranial myxoid mesenchymal tumors with EWSR1::CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? Brain Pathol (zurich, Switzerland) 28(2):183–191. https://doi.org/10.1111/bpa.12504
Cazzato G, Lupo C, Casatta N et al (2022) Angiomatoid fibrous histiocytoma (AFH) of the right arm: an exceptional case with pulmonary metastasis and confirmatory EWSR1::CREB1 translocation. Diagnostics (basel, Switzerland) 12(11):2616. https://doi.org/10.3390/diagnostics12112616
Chen Z, Yang Y, Chen R, Ng CS, Shi H (2020) Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion: a case report and review of the literature. Diagn Pathol 15(1):15. https://doi.org/10.1186/s13000-020-00930-2
Costa MJ, Weiss SW (1990) Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol 14(12):1126–1132
Garnier L, Fenouil T, Pissaloux D et al (2021) Intracranial non-myxoid angiomatoid fibrous histiocytoma with EWSR1::CREB1 transcript fusion treated with doxorubicin: a case report. Mol Clin Oncol 15(1):131. https://doi.org/10.3892/mco.2021.2293
Gilani SM, Kowalski PJ (2014) Inflammatory myofibroblastic tumour: a rare entity with wide differential diagnosis. Pathologica 106(1):1–6
Goh YW, Spagnolo DV, Platten M et al (2001) Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology 39(5):514–524. https://doi.org/10.1046/j.1365-2559.2001.01277.x
Gołota J, Osowiecka K, Orłowski T (2019) Primary pulmonary sarcoma—treatment outcomes depending on the different types of radical operation. Kardiochirurgia i Torakochirurgia Polska Polish J Cardio-Thoracic Surg 16(1):1–6. https://doi.org/10.5114/kitp.2019.83938
Gong QX, Zhang ZH, Fan QH (2018) Zhonghua bing li xue za zhi Chin J Pathol 47(9): 700–705. https://doi.org/10.3760/cma.j.issn.0529-5807.2018.09.010
Gui H, Sussman RT, Jian B, Brooks JS, Zhang PJL (2020) Primary pulmonary myxoid sarcoma and myxoid angiomatoid fibrous histiocytoma: a unifying continuum with shared and distinct features. Am J Surg Pathol 44(11):1535–1540. https://doi.org/10.1097/PAS.0000000000001548
Hashimoto H, Tsugeno Y, Sugita K, Inamura K (2019) Mesenchymal tumors of the lung: diagnostic pathology, molecular pathogenesis, and identified biomarkers. J Thoracic Dis 11(1):S9–S24. https://doi.org/10.21037/jtd.2018.12.04
Henriques de Gouveia R (2023) Inflammatory myofibroblastic tumor of the heart: a brief overview. Revista Portuguesa De Cardiologia Portuguese J Cardiol 42(2):171–172. https://doi.org/10.1016/j.repc.2022.12.010
Hisaoka M, Hashimoto H (2005) Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int 55(8):453–463. https://doi.org/10.1111/j.1440-1827.2005.01853.x
Inayama Y, Hayashi H, Ogawa N, Mitsui H, Nakatani Y (2001) Low-grade pulmonary myxoid sarcoma of uncertain histogenesis. Pathol Int 51(3):204–210. https://doi.org/10.1046/j.1440-1827.2001.01180.x
Jeon YK, Moon KC, Park SH, Chung DH (2014) Primary pulmonary myxoid sarcomas with EWSR1::CREB1 translocation might originate from primitive peribronchial mesenchymal cells undergoing (myo)fibroblastic differentiation. Virchows Archiv Int J Pathol 465(4):453–461. https://doi.org/10.1007/s00428-014-1645-z
Jo VY, Fletcher CD (2015) Myoepithelial neoplasms of soft tissue: an updated review of the clinicopathologic, immunophenotypic, and genetic features. Head Neck Pathol 9(1):32–38. https://doi.org/10.1007/s12105-015-0618-0
Kao YC, Sung YS, Zhang L et al (2017) EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol 41(4):482–490. https://doi.org/10.1097/PAS.0000000000000788
Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N (2018) Inflammatory myofibroblastic tumor of the lung. Adv Respir Med 86(1):27–35. https://doi.org/10.5603/ARM.2018.0007
Kim S, Song SY, Yun JS, Choi YD, Na KJ (2017) Primary pulmonary myxoid sarcoma located in interlobar fissure without parenchymal invasion. Thoracic Cancer 8(5):535–538. https://doi.org/10.1111/1759-7714.12469
Koelsche C, Tavernar L, Neumann O et al (2020) Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1. Virchows Archiv Int J Pathol 476(5):787–791. https://doi.org/10.1007/s00428-019-02716-4
Matsukuma S, Hisaoka M, Obara K, Kono T, Takeo H, Sato K, Hata Y (2012) Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion, resembling extraskeletal myxoid chondrosarcoma: case report with a review of Literature. Pathol Int 62(12):817–822. https://doi.org/10.1111/pin.12014
Ngo C, Grinda T, Boilève A et al (2022) Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1::CREB1 fusion and ALK overexpression. Ann Oncol 33(8):848–850. https://doi.org/10.1016/j.annonc.2022.05.003
Nicholson AG, Baandrup U, Florio R, Sheppard MN, Fisher C (1999) Malignant myxoid endobronchial tumour: a report of two cases with a unique histological pattern. Histopathology 35(4):313–318. https://doi.org/10.1046/j.1365-2559.1999.00724.x
Nicholson AG, Tsao MS, Beasley MB et al (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thoracic Oncol 17(3):362–387. https://doi.org/10.1016/j.jtho.2021.11.003
Nishimura T, Ii T, Inamori O, Konishi E, Yoshida A (2023) Primary pulmonary myxoid sarcoma with EWSR1::ATF1 fusion: a case report. Int J Surg Pathol 31(1):88–91. https://doi.org/10.1177/10668969221095457
Opitz I, Lauk O, Schneiter D et al (2019) Intraluminal EWSR1::CREB1 gene rearranged, low-grade myxoid sarcoma of the pulmonary artery resembling extraskeletal myxoid chondrosarcoma (EMC). Histopathology 74(3):526–530. https://doi.org/10.1111/his.13773
Prieto-Granada CN, Ganim RB, Zhang L, Antonescu C, Mueller J (2017) Primary pulmonary myxoid sarcoma: a newly described entity-report of a case and review of the literature. Int J Surg Pathol 25(6):518–525. https://doi.org/10.1177/1066896917706413
Rossi S, Szuhai K, Ijszenga M et al (2007) EWSR1::CREB1 and EWSR1::ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res 13(24):7322–7328. https://doi.org/10.1158/1078-0432.CCR-07-1744
Scapa JV, Cloutier JM, Raghavan SS, Peters-Schulze G, Varma S, Charville GW (2021) DDIT3 immunohistochemistry is a useful tool for the diagnosis of myxoid liposarcoma. Am J Surg Pathol 45(2):230–239. https://doi.org/10.1097/PAS.0000000000001564
Shilo K, Miettinen M, Travis WD, Timens W, Nogueira R, Franks TJ (2006) Pulmonary microcystic fibromyxoma: report of 3 cases. Am J Surg Pathol 30(11):1432–1435. https://doi.org/10.1097/01.pas.0000213279.53338.32
Smith SC, Palanisamy N, Betz BL et al (2014) At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases. Histopathology 65(1):144–146. https://doi.org/10.1111/his.12354
Stacchiotti S, Baldi GG, Morosi C, Gronchi A, Maestro R (2020) Extraskeletal myxoid chondrosarcoma: state of the art and current research on biology and clinical management. Cancers 12(9):2703. https://doi.org/10.3390/cancers12092703
Stockman DL, Miettinen M, Suster S et al (2012) Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol 36(6):857–868. https://doi.org/10.1097/PAS.0b013e31824644ac
Subbiah V, Holmes O, Gowen K et al (2016) Activity of c-Met/ALK inhibitor crizotinib and multi-kinase VEGF inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor harboring EWSR1::CREB1 fusion. Oncology 91(6):348–353. https://doi.org/10.1159/000449204
Thway K, Fisher C (2012) Tumors with EWSR1::CREB1 and EWSR1::ATF1 fusions: the current status. Am J Surg Pathol 36(7):e1–e11. https://doi.org/10.1097/PAS.0b013e31825485c5
Thway K, Fisher C (2015) Angiomatoid fibrous histiocytoma: the current status of pathology and genetics. Arch Pathol Lab Med 139(5):674–682. https://doi.org/10.5858/arpa.2014-0234-RA
Thway K, Nicholson AG, Lawson K et al (2011) Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion: a new tumor entity. Am J Surg Pathol 35(11):1722–1732. https://doi.org/10.1097/PAS.0b013e318227e4d2
Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thoracic Oncol 10(9):1243–1260. https://doi.org/10.1097/JTO.0000000000000630
Wang Z, Zhang L, Ren L et al (2021) Distinct clinicopathological features of pulmonary primary angiomatoid fibrous histiocytoma: a report of four new cases and review of the literature. Thoracic Cancer 12(3):314–323. https://doi.org/10.1111/1759-7714.13727
Wu Y, Luo Y, Gong Y, Yang R, Ding L, Guo B (2021) Primary pulmonary myxoid sarcoma: report of one case and literature review. Int J Clin Exp Pathol 14(2):230–237. https://doi.org/10.1002/anie.202116068
Yanagida R, Balzer BL, Mckenna RJ, Fuller CB (2017) Primary pulmonary myxoid sarcoma, a potential mimic of metastatic extraskeletal myxoid chondrosarcoma. Pathology 49(7):792–794. https://doi.org/10.1016/j.pathol.2017.08.015
Yuliana S, Hayati F (2022) CT findings of a large primary pulmonary myxoid sarcoma: a case report. Radiol Case Rep 17(9):3331–3335. https://doi.org/10.1016/j.radcr.2022.06.029
Zhou Q, Lu G, Liu A, Kohno T (2012) Extraskeletal myxoid chondrosarcoma in the lung: asymptomatic lung mass with severe anemia. Diagn Pathol 7:112. https://doi.org/10.1186/1746-1596-7-112
Funding
This work was supported by Beijing Xisike Clinical Oncology Research Foundation (Y-HS202201-0084).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by XM, JC, and LY. Conceptualization and supervision were performed by HL. The first draft of the manuscript was written by XM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Miao, X., Chen, J., Yang, L. et al. Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion: a literature review. J Cancer Res Clin Oncol 150, 108 (2024). https://doi.org/10.1007/s00432-024-05634-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00432-024-05634-4